_1788849633 20260908064033000 Rovedar Daryoushbabazadeh@gmail.com Rovedar Journal of Lab Animal Research J Lab Anim. Res 2980-9703 08 30 2026 5 4 Hadis Farokhmoradi https://orcid.org/0009-0001-6959-2345 Parsa Jahani https://orcid.org/0000-0001-7073-2205 Sima Saravani https://orcid.org/0000-0001-7314-3182 Seyedeh Maryam Moallem https://orcid.org/0000-0001-5289-8455 Mohammad Amin Ghasemzadeh https://orcid.org/0009-0002-3661-5886 Parsa Taher https://orcid.org/0009-0009-7292-0248 Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, and chronic gastric ulceration represents an important precursor lesion in a subset of patients. This narrative review aimed to synthesize evidence published between 2015 and 2026 on the etiology and pathogenesis of gastric ulcer, current therapeutic strategies, the preclinical roles of laboratory animals, treatment failures, and the transition from gastric ulcer to gastric cancer. The progression from chronic inflammation to malignancy is driven by a complex interplay of bacterial virulence factors, host responses, and molecular alterations. Laboratory animal models have provided important preclinical evidence for evaluating gastric mucosal injury, histopathological changes, diagnostic biomarkers, and carcinogenic progression. In particular, rodent and mouse models have supported the development of molecular and fluorescence-based imaging approaches for detecting ulcerative, dysplastic, and malignant gastric lesions. Helicobacter pylori (H. pylori) infection and prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary etiological factors in the development of gastric ulcer, while host susceptibility, environmental influences, and microbial interactions further contribute to disease progression. Recent advances have improved understanding of the molecular mechanisms underlying gastric mucosal injury, ulcer healing, and carcinogenesis, including CagA-mediated signaling, the spermine oxidase (SMOX) pathway, and microbiota-derived metabolites. Despite the widespread use of proton pump inhibitors and H. pylori eradication diets, increasing antibiotic resistance and refractory ulcers continue to limit treatment success. Emerging biomarkers, innovative acid-suppressive agents, microbiome-based strategies, and advanced imaging technologies present promising strategies for improving diagnosis and treatment. Integrating findings from experimental animal models with clinical evidence could improve diagnostic timing, risk prediction, and the development of targeted strategies to prevent the progression of gastric ulcers to gastric cancer. 08 30 2026 94 102 https://creativecommons.org/licenses/by/4.0 10.58803/jlar.v5i4.113 https://jlar.rovedar.com/index.php/JLAR/article/view/113 https://jlar.rovedar.com/index.php/JLAR/article/download/113/150 https://jlar.rovedar.com/index.php/JLAR/article/download/113/150 10.1016/S0140-6736(16)32404-7 10.1097/MCG.0000000000001719 10.1111/apt.16592 10.1007/978-3-031-47331-9_8 10.7759/cureus.37080 10.1007/s13167-017-0081-y 10.1111/hel.12635 10.1016/j.cgh.2019.07.045 10.3389/fmicb.2021.630852 10.1186/s13045-024-01654-2 10.3390/jcm14155318 10.18632/oncotarget.19415 10.1002/9781119423195.ch11 10.1007/978-3-030-15138-6_5 10.3390/microorganisms11051312 10.1002/ame2.12349 10.1016/j.jpha.2023.02.011 10.3389/fonc.2021.643669 10.1111/hel.12386 10.3390/microorganisms9122502 10.4291/wjgp.v16.i2.107052 10.3389/fcimb.2023.1062803 10.3390/ijms24032895 10.1080/19490976.2021.1909459 10.1016/j.gastha.2025.100860 10.1016/j.jcmgh.2019.05.008 10.1186/s13046-024-03034-7 10.1038/s41435-021-00146-4 10.1080/07357907.2024.2437614 10.1038/s41388-020-1304-6 10.3390/nu13124281 10.1007/s13402-023-00802-z 10.1136/gutjnl-2025-335103 10.1038/s41418-023-01254-6 10.3390/diseases10030035 10.3390/cancers18020331 10.21614/chirurgia.3147 Żurawik-Duszka A, Pobiega M, Kasperski T, and Chmielarczyk A. Unraveling the complexity of Helicobacter pylori: Virulence factors, biofilm formation, and antibiotic resistance. J Physiol Pharmacol. 2026; 77(1): 49-62. DOI: 10.26402/jpp.2026.1.04 10.1038/s41396-023-01483-0 10.1136/gutjnl-2014-307595 10.3390/jcm11113141 10.1007/978-3-031-47331-9_2 10.3390/antibiotics12020191 10.1001/jama.2016.11764 10.1152/physrev.00016.2019 10.3238/arztebl.2016.0477 10.3390/ijms26031181 10.1186/s12916-016-0718-z 10.1007/s00228-025-03912-9 Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020; 69(12): 2093-2112. DOI: 10.1136/gutjnl-2020-322368 10.3390/life12122038 10.3390/ijms18081699 10.3389/fmicb.2025.1652943 10.1080/14787210.2022.2078308 10.3390/molecules23071751 10.3390/ph18010044 10.1080/14656566.2020.1845649 10.1016/S0140-6736(16)31592-6 10.1007/s10555-020-09925-3 10.1016/S2666-5247(22)00121-5 10.1038/s41575-021-00449-x 10.1111/hel.13103 10.7717/peerj.15121 10.3390/ijms252312826 10.1080/17425255.2018.1461835 10.1111/apt.16295 10.1007/s00464-025-12521-7 10.1002/9781118512074.ch56 10.3389/fcimb.2025.1516237 10.1038/s41422-020-0332-7 10.3390/microorganisms14061241 10.3748/wjg.v23.i9.1521 10.3390/pathogens10091099 10.1097/pp9.0000000000000002 10.1002/cam4.680 10.3748/wjg.v29.i30.4616 10.1177/2050640618770013 10.3389/fgene.2017.00020 10.5772/intechopen.1011730 10.1007/s12029-021-00734-7 10.3892/ol.2016.5506 10.3389/fcell.2024.1513426 10.3390/antibiotics13060484 10.1016/j.immuni.2019.06.025 10.3390/cells10010027 10.3389/fmicb.2018.00005 10.1038/nature17039 10.3892/etm.2016.3293 10.1002/mco2.658 10.1080/17474124.2019.1542299 10.1136/gutjnl-2020-322368 10.7759/cureus.97640 10.1007/s00228-023-03534-z 10.3389/fphar.2025.1673200 10.1038/s41390-018-0071-3 10.3390/medicina61091569 10.1080/17425255.2022.2098107 10.2147/TCRM.S80437